As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Orchestra BioMed, based in New Hope, successfully raised $111 million in just five days to support the advancement of two of its flagship technologies ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

Ligand expects full-year earnings in the range of $6.70 to $7 per share, with revenue in the range of $200 million to $225 million. This story was generated by Automated Insights ( ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

They have developed a rapid method for extracting europium from electronic waste using a sulfur-based compound.

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key ...

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create ...

Eneos Corp. (Tokyo) has announced the development of alkylphosphine with a triisobutylene (TIB) backbone (TIB phosphine ...